D Heinl1, C A C Prinsen2, S Deckert3, J R Chalmers4, A M Drucker5, R Ofenloch6, R Humphreys7, T Sach8, S L Chamlin9, J Schmitt3, C Apfelbacher1,10. 1. Medical Sociology, Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany. 2. VU University Medical Center, Department of Epidemiology and Biostatistics, EMGO+ Institute for Health and Care Research, Amsterdam, The Netherlands. 3. Centre for Evidence-based Healthcare, Medizinische Fakultät Carl Gustav Carus, TU Dresden, Dresden, Germany. 4. Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK. 5. Division of Dermatology, University Health Network, Toronto, ON, Canada. 6. Department of Clinical Social Medicine, University Hospital Heidelberg, Heidelberg, Germany. 7. Budleigh Salterton, Devon, UK. 8. Norwich Medical School, University of East Anglia, Norwich, UK. 9. Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 10. Division of Public Health and Primary Care, Brighton and Sussex Medical School, Falmer, UK.
Abstract
BACKGROUND: The Harmonising Outcome Measures for Eczema (HOME) initiative has identified quality of life (QoL) as a core outcome domain to be evaluated in every eczema trial. It is unclear which of the existing QoL instruments is most appropriate for this domain. Thus, the aim of this review was to systematically assess the measurement properties of existing measurement instruments developed and/or validated for the measurement of QoL in adult eczema. METHODS: We conducted a systematic literature search in PubMed and Embase identifying studies on measurement properties of adult eczema QoL instruments. For all eligible studies, we assessed the adequacy of the measurement properties and the methodological quality with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. A best evidence synthesis summarizing findings from different studies was the basis to assign four degrees of recommendation (A-D). RESULTS: A total of 15 articles reporting on 17 instruments were included. No instrument fulfilled the criteria for category A. Six instruments were placed in category B, meaning that they have the potential to be recommended depending on the results of further validation studies. Three instruments had poor adequacy in at least one required adequacy criterion and were therefore put in category C. The remaining eight instruments were minimally validated and were thus placed in category D. CONCLUSIONS: Currently, no QoL instrument can be recommended for use in adult eczema. The Quality of Life Index for Atopic Dermatitis (QoLIAD) and the Dermatology Life Quality Index (DLQI) are recommended for further validation research.
BACKGROUND: The Harmonising Outcome Measures for Eczema (HOME) initiative has identified quality of life (QoL) as a core outcome domain to be evaluated in every eczema trial. It is unclear which of the existing QoL instruments is most appropriate for this domain. Thus, the aim of this review was to systematically assess the measurement properties of existing measurement instruments developed and/or validated for the measurement of QoL in adult eczema. METHODS: We conducted a systematic literature search in PubMed and Embase identifying studies on measurement properties of adult eczema QoL instruments. For all eligible studies, we assessed the adequacy of the measurement properties and the methodological quality with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. A best evidence synthesis summarizing findings from different studies was the basis to assign four degrees of recommendation (A-D). RESULTS: A total of 15 articles reporting on 17 instruments were included. No instrument fulfilled the criteria for category A. Six instruments were placed in category B, meaning that they have the potential to be recommended depending on the results of further validation studies. Three instruments had poor adequacy in at least one required adequacy criterion and were therefore put in category C. The remaining eight instruments were minimally validated and were thus placed in category D. CONCLUSIONS: Currently, no QoL instrument can be recommended for use in adult eczema. The Quality of Life Index for Atopic Dermatitis (QoLIAD) and the Dermatology Life Quality Index (DLQI) are recommended for further validation research.
Authors: P P Vakharia; R Chopra; R Sacotte; N Patel; S Immaneni; T White; R Kantor; D Y Hsu; E L Simpson; J I Silverberg Journal: Br J Dermatol Date: 2018-03-06 Impact factor: 9.302
Authors: K R Patel; V Singam; P P Vakharia; R Chopra; R Sacotte; N Patel; S Immaneni; R Kantor; D Y Hsu; J I Silverberg Journal: Br J Dermatol Date: 2018-11-12 Impact factor: 9.302
Authors: Daniel Heinl; Cecilia A C Prinsen; Aaron M Drucker; Robert Ofenloch; Rosemary Humphreys; Tracey Sach; Carsten Flohr; Christian Apfelbacher Journal: Syst Rev Date: 2016-02-09
Authors: F M Vermeulen; L A A Gerbens; A L Bosma; C J Apfelbacher; A D Irvine; B W M Arents; S Barbarot; M Deleuran; L F Eichenfield; A Manca; J Schmitt; C Vestergaard; D Wall; S Weidinger; M A Middelkamp-Hup; P I Spuls; C Flohr Journal: Br J Dermatol Date: 2019-06-23 Impact factor: 9.302